Status:
RECRUITING
Efficacy of Remifentanil in Preventing Emergence Agitation
Lead Sponsor:
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Conditions:
Emergence Agitation
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The primary aim of the study was to test the hypothesis that remifentanil administered for analgesia prevents emergence agitation more effectively than fentanyl and N2O in patients undergoing rhinopla...
Eligibility Criteria
Inclusion
- The study included patients over the age of 18, planned to undergo rhinoplasty by the plastic and reconstructive surgery department, and American Society of Anesthesiologist (ASA) I-II.
- \-
Exclusion
- Patients with a known history of allergy to the drugs to be administered in the study, ASA III and above, body mass index (BMI) 35\>kg/m2, younger than 18 years of age, any problems that would prevent general anesthesia in the preoperative evaluation (upper respiratory tract infection, etc.), and those who did not agree to participate in the study were excluded from the study.
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT06539013
Start Date
August 1 2024
End Date
October 1 2024
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Health Sciences University Gazi Yaşargil Training and Research Hospital
Diyarbakır, Kayapınar, Turkey (Türkiye), 21070